Results 231 to 240 of about 394,010 (304)

Uric Acid in Metabolic Dysfunction‐Associated Steatotic Liver Disease

open access: yesPortal Hypertension &Cirrhosis, EarlyView.
MASLD is the most prevalent chronic liver disease worldwide, yet effective pharmacological treatments remain limited. Hyperuricemia is now recognized as a key driver of hepatic steatosis, inflammation, and fibrosis, with elevated serum uric acid levels independently predicting hepatocellular carcinoma and liver‐related mortality.
Rong Wang   +5 more
wiley   +1 more source

Discordance of Small Dense LDL Cholesterol Beyond LDL Cholesterol or Non-HDL Cholesterol and Carotid Plaque. [PDF]

open access: yesJACC Asia
Wang J   +9 more
europepmc   +1 more source

Modeling of Disease Progression of Type 2 Diabetes Using Real‐World Data: Quantifying Competing Risks of Morbidity and Mortality

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 606-615, March 2025.
ABSTRACT Type 2 diabetes (T2D) is a progressive metabolic disorder that could be an underlying cause of long‐term complications that increase mortality. The assessment of the probability of such events could be essential for mortality risk management. This work aimed to establish a framework for risk predictions of macrovascular complications (MVC) and
Hanna Kunina   +2 more
wiley   +1 more source

Safety of 12‐Months Administration of Ashwagandha (Withania somnifera) Standardized Root Extract in Healthy Adults: A Prospective, Observational Study

open access: yesPhytotherapy Research, EarlyView.
ABSTRACT Ashwagandha, an adaptogen, is an important herb of Ayurveda used as a Rasayana for its various health benefits. This prospective, multi‐center, observational clinical study evaluates the safety (clinical and laboratory) of a standardized Ashwagandha Root Extract (ARE) on long‐term administration over 12 months. Male and female adults (N = 191)
Jaising Salve   +6 more
wiley   +1 more source

Monocyte to HDL cholesterol ratio predicts obesity-associated cardiac dysfunction. [PDF]

open access: yesJ Biomed Res
Zhao C   +15 more
europepmc   +1 more source

Association of insomnia, insulin resistance traits, and cardiovascular disease risk: A two‐step Mendelian randomization study

open access: yesSleep Research, EarlyView.
The causal roles of metabolic traits in mediating the effects of insomnia on CVDs. CAD, coronary artery disease; HbA1c, hemoglobin A1c; HDL‐C, high‐density lipoprotein cholesterol; IR, insulin resistance; MI, myocardial infarction; TG, triglyceride; T2DM, type 2 diabetes.
Binhe Yu   +12 more
wiley   +1 more source

Advances in cholesterol and lipoproteins detection for healthcare: A review

open access: yesVIEW, EarlyView.
Cholesterol is one of the main biomarkers related to the development of cardiovascular diseases. Its detection still relies on traditional methods of analysis, such as gas and liquid chromatographies. Detection of free cholesterol in saliva with redox or enzymatic sensors or detection of lipoproteins in blood with aptamer sensors are currently the most
Jacopo Giaretta   +7 more
wiley   +1 more source

A Case of Acquired LCAT Deficiency with the Discrepancy between Spontaneous Resolution of Proteinuria and Continually Low HDL Cholesterol Levels. [PDF]

open access: yesJ Atheroscler Thromb
Matsuo M   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy